Immunome, Inc.
IMNM
$7.17
-$0.23-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.91% | 23.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.91% | 23.10% | |||
| Cost of Revenue | 28.74% | 27.91% | |||
| Gross Profit | -31.68% | -28.34% | |||
| SG&A Expenses | 9.66% | 36.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.85% | 29.57% | |||
| Operating Income | -26.89% | -30.03% | |||
| Income Before Tax | -70.38% | -30.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -70.38% | -30.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -70.38% | -30.39% | |||
| EBIT | -26.89% | -30.03% | |||
| EBITDA | -27.05% | -30.94% | |||
| EPS Basic | -63.25% | -29.80% | |||
| Normalized Basic EPS | -25.42% | -34.91% | |||
| EPS Diluted | -63.72% | -29.80% | |||
| Normalized Diluted EPS | -25.42% | -34.91% | |||
| Average Basic Shares Outstanding | 4.37% | 0.45% | |||
| Average Diluted Shares Outstanding | 4.37% | 0.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||